Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Status:
Completed
Trial end date:
2015-04-30
Target enrollment:
Participant gender:
Summary
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in
patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or
pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15
years) or have known EGFR activating mutation; or patients with HER 2 amplification or
mutation.